RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

NCT04849377 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped lack of eligible participants due to change in study criterias

Conditions

Human Papillomavirus (HPV)
Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

RADIATION: RT 50 Gy
RADIATION: RT 54 GY
RADIATION: RT 60 GY
OTHER: Induction Therapy
DRUG: Carboplatin
DRUG: Cisplatin 200
DRUG: Cisplatin 240

Sponsor

Icahn School of Medicine at Mount Sinai